Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03088540 · OUTCOME

Number of Participants With Neutralizing Antibodies (NAb)

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 73.5 months

What was measured

The NAb status of each participant was categorized as follows: * Negative - Samples that tested negative in the ADA assay, or samples positive in the ADA assay but tested negative in the NAb assay * Positive

Analysis population: The NAb analysis set included all treated participants from the AAS who received any amount of study drug, with at least one non-missing NAb result (either assigned or assessed) following the first dose of study drug.

Groups in this outcome

Cemiplimab

Participants received cemiplimab monotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cemiplimab255

Reported measurements

Source class 1

NAb Negative

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab255Not reportedNot reportedNot reportedNot reported

NAb Positive

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        255
      title
      NAb Negative
    2. measurements
      1. group Id
        OG000
        value
        0
      title
      NAb Positive
denoms
  1. counts
    1. group Id
      OG000
      value
      255
    units
    Participants
description
The NAb status of each participant was categorized as follows: * Negative - Samples that tested negative in the ADA assay, or samples positive in the ADA assay but tested negative in the NAb assay * Positive
groups
  1. description
    Participants received cemiplimab monotherapy
    id
    OG000
    title
    Cemiplimab
param Type
COUNT_OF_PARTICIPANTS
population Description
The NAb analysis set included all treated participants from the AAS who received any amount of study drug, with at least one non-missing NAb result (either assigned or assessed) following the first dose of study drug.
reporting Status
POSTED
time Frame
Up to 73.5 months
title
Number of Participants With Neutralizing Antibodies (NAb)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice